Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
There are completed and ongoing trials of VLS-01, a buccal film formulation of DMT, in treating patients with treatment-resistant depression. In a completed Phase 1 trial, this formulation was found to be well tolerated, with adverse effects being mild or moderate. As of April 2026, there are phase 2 trials ongoing in the United States and Australia.
=== Protein radical formation === Glycyl radical enzyme activating enzymes (GRE-AEs) are radical SAM subset that can house a stable and catalytically essential glycyl radical in their active state. The underlying chemistry is considered to be the simplest in the radical SAM superfamily with H-atom abstraction by the 5'-dAdo radical being the product of the reaction. A few examples include:
Vaccination campaigns began in Porto Alegre on 20 January 2021. Starting in January, the municipal government began to not keep second doses of the vaccine, immediately using up all of the supplies that they received from the Programa Nacional de Imunizações (PNI). This created delays in second doses by the end of April and the beginning of May, when there was a further delay in the sending out of doses of CoronaVac throughout Brazil. Long lines formed as a result of people waiting for the vaccine, but there were not enough doses to go around, implying that there were people who were immunized during a period longer than the four weeks recommended by the manufacturers. Melo recorded a video, which was released on social media, apologizing to the populace for the delays and claiming that the Ministry of Health was responsible for the error. Upon receiving the supplies of the Pfizer/BioNTech vaccine, the municipal government decided to keep the shots to be able to give a second dose, to avoid the same issue that occurred with the CoronaVac vaccines. In March, the Consortium of the Association of Municipalities of the Porto Alegre Metropolitan Region (Granpal), integrated by Porto Alegre's city government, made a proposal to buy doses of the Sputnik V vaccine that would be meant for, by law, the PNI. The purchase, however, did not go forward.
== Factors == First-pass metabolism may occur in the liver (for propranolol, lidocaine, clomethiazole, and nitroglycerin) or in the gut (for benzylpenicillin and insulin). The four primary systems that affect the first pass effect of a drug are the enzymes of the gastrointestinal lumen, gastrointestinal wall enzymes, bacterial enzymes and hepatic enzymes.
Sources: en.wikipedia.org
== Side effects == The most common side effect of verapamil is constipation (7.3%). While the definite mechanism by which verapamil causes constipation has not been studied, studies have been conducted to rule out mechanisms of actions that might yield this adverse effect. A 1992 study found that verapamil causes a delay in colonic transit but does not affect upper gastrointestinal transit. Other side effects include dizziness (3.3%), nausea (2.7%), low blood pressure (2.5%), and headache 2.2%. Other side effects seen in less than 2% of the population include: edema, congestive heart failure, pulmonary edema, diarrhea, fatigue, elevated liver enzymes, shortness of breath, low heart rate, atrioventricular block, rash and flushing. Along with other calcium channel blockers, verapamil is known to induce gingival enlargement.
=== Other endurance sports === In triathlon, 2004 Hawaii Ironman winner Nina Kraft, was disqualified for a positive test to EPO. She remains the only Hawaii Ironman winner to be disqualified for doping offences. Sports lawyer Michelle Gallen has said that the pursuit of doping athletes has turned into a modern-day witch-hunt.
At 19:10, Xi, wearing a Chinese tunic suit, and Peng, who wore a long-sleeved V-neck gown in red, returned to the White House for a state dinner, where Trump and his wife greeted them. As the state banquet was held close to the Mid-Autumn Festival, the White House arranged the song "The Moon Represents My Heart" as the entrance music. The dinner was planned by First Lady Melania Trump and consisted of American dishes with subtle Chinese influence. Schramsberg “Blanc De Noir” was chosen for the toast, honoring the "Toast of Peace" shared between President Richard Nixon and Premier Zhou Enlai in 1972. Tables were covered with bright red linens and were adorned with red candles and flower arrangements of red dahlias and ranunculus, while guests ate off red tablecloths; red is a symbol of luck and good fortune in Chinese culture. A three‑course meal of yellow squash velouté, sesame crusted sea bass, and vanilla crémeux & White House honey ice cream was served at the dinner. The dinner was accompanied by musical performances by Christopher Macchio, the United States Marine Band, the United States Marine Drum and Bugle Corps, the United States Army Chorus, and the United States Army Strings. Other members of the Chinese delegation, including Cai Qi and Wang Yi, wore Chinese tunic suits like Xi; while it is common for the Chinese leader to wear such a suit in state dinners, other members of the Chinese delegation usually wore Western suits in other occasions.
=== Wound care and dressings === Caring for wounds and ulcers that have been started and the use of creams are also considerations in preventing worsening to ulcers and new primary ulcers. It is unclear if creams containing fatty acids are effective in reducing incidence of pressure ulcers compared to creams without fatty acids. It is also unclear if silicone dressings reduce pressure ulcer incidence. There is no evidence that massage reduces pressure ulcer incidence. Controlling the heat and moisture levels of the skin surface, known as skin microclimate management, may also play a role in the prevention and control of pressure ulcers. Skin care is also important because damaged skin does not tolerate pressure. However, skin that is damaged by exposure to urine or stool is not considered a pressure ulcer. These skin wounds should be classified as Incontinence Associated Dermatitis.
=== 2021 === By January 2021, North Korea's borders had been closed for one year. According to South Korean analysis, trade between North Korea and China had fallen by 76%. In March, North Korea decided not to participate in the 2020 Summer Olympics in Tokyo due to concerns over potential exposure to COVID-19. As a result, the Olympic Committee of the Democratic People's Republic of Korea was suspended by the International Olympic Committee (IOC) through the end of 2022, thus prohibiting the country from participating in the 2022 Winter Olympics in Beijing. In April 2021, Russian diplomats in Pyongyang said that North Korea had "total restrictions that are unprecedented in their severity", as well as severe shortages. According to the diplomatic mission, many foreign diplomats had left the country, leaving less than 290 foreigners in North Korea, including only nine ambassadors and four chargés d'affaires. Later that month, Kim Jong Un said North Korea was facing its "worst-ever situation" in reference to the economic downturn due to COVID-19; he called for the party to wage another Arduous March to fight the severe economic difficulties. However, the translation as "worst-ever situation" has been disputed by some analysts as an exaggeration, with the original speech (극난한) translatable as simply a very hard, or difficult situation. The translation as "worst-ever" had also been previously used in the 8th Congress of the Workers' Party of Korea to refer to the past five years, yet the economy is in nowhere near as much difficulty as in the 1990s.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.